Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clonidine GH stimulation test to differentiate MSA from idiopathic late onset cerebellar ataxia: a prospective, controlled study

  • 21 Accesses

Abstract

Introduction

Despite the consensus criteria for multiple system atrophy (MSA), the diagnosis of MSA of cerebellar type (MSA-C) may be difficult in the early stage of the disease. There are several differential diagnoses including idiopathic late-onset cerebellar ataxias (ILOCA) and it is often necessary to wait for clinical worsening so that the criteria can be met. Our aim was to assess the efficacy of clonidine growth hormone test (CGH test) to distinguish MSA-C from ILOCA in the early stage of the disease.

Methods

Within our cohort of late-onset sporadic, progressive cerebellar ataxia, the group of patients meeting the criteria for possible or probable MSA was compared to the ILOCA group. Clinical and paraclinical examination including CGH test were repeated during the prospective follow-up.

Results

Eighty-six patients were recruited, including 42 patients in the MSA group and 44 ILOCA patients with a mean follow-up of 33 months. At the inclusion visit, CHG test was pathological for 31% MSA of patients and 18.2% of ILOCA patients (p = 0.35). During the follow-up, 52.4% of MSA-C had a pathological CGH test, while only 20.5% of ILOCA (p < 0.01). CGH test had a sensitivity of 69.1% and a specificity of 68.2%, (p < 0.001) for MSA-C patients; CGH test allows in three quarters of cases, if negative, to rule out a probable MSA-C (negative predictive value of 75%, p = 0.0014).

Conclusion

This prospective, controlled study showed that CGH test could be helpful in clinical practice to differentiate MSA-C from ILOCA in the early stage of the disease.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676. https://doi.org/10.1212/01.wnl.0000324625.00404.15

  2. 2.

    Gebus O, Montaut S, Monga B et al (2017) Deciphering the causes of sporadic late-onset cerebellar ataxias: a prospective study with implications for diagnostic work. J Neurol 264(6):1118–1126. https://doi.org/10.1007/s00415-017-8500-5

  3. 3.

    Cao B, Zhang L, Zou Y et al (2018) Survival analysis and prognostic nomogram model for multiple system atrophy. Parkinsonism Relat Disord 54:68–73. https://doi.org/10.1016/j.parkreldis.2018.04.016

  4. 4.

    Young TM, Asahina M, Watson L, Mathias CJ (2006) Hemodynamic effects of clonidine in two contrasting models of autonomic failure: Multiple system atrophy and pure autonomic failure. Mov Disord 21(5):609–615. https://doi.org/10.1002/mds.20755

  5. 5.

    Kimber J, Watson L, Mathias C (1997) Distinction of idiopathic Parkinson’s disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. The Lancet 349(9069):1877–1881. https://doi.org/10.1016/S0140-6736(96)10168-9

  6. 6.

    Pellecchia MT, Pivonello R, Colao A, Barone P (2006) Growth hormone stimulation tests in the differential diagnosis of Parkinson’s disease. Clin Med Res 4(4):322–325

  7. 7.

    Zhang K, Zeng Y, Song C, Fu Y, Wan Q (2010) The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson’s disease. J Neurol 257(9):1486–1491. https://doi.org/10.1007/s00415-010-5556-x

  8. 8.

    A validation exercise on the new consensus criteria for multiple system atrophy-Osaki (2009) Movement Disorders-Wiley Online Library. https://onlinelibrary-wiley-com.scd-rproxy.u-strasbg.fr/doi/pdf/10.1002/mds.22826. Accessed 11 Sep 2019

  9. 9.

    Koga S, Aoki N, Uitti RJ et al (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85(5):404–412. https://doi.org/10.1212/WNL.0000000000001807

  10. 10.

    Stankovic I, Quinn N, Vignatelli L et al (2019) A critique of the second consensus criteria for multiple system atrophy. Mov Disord 34(7):975–984. https://doi.org/10.1002/mds.27701

Download references

Author information

Correspondence to Mathieu Anheim.

Ethics declarations

Conflicts of interest

Mathieu Anheim declares honoraria and/or grants from AbbVie, Teva, Merz, Orkyn, Aguettant, Actelion Pharmaceuticals, Johnson and Johnson. Christine Tranchant declares honoraria from Merz and Allergan. Thomas Wirth received research grants from the Revue Neurologique, the Fondation Planiol and the APTES association and travel funding from LVL medical.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 33 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bonnard, C., Wirth, T., Gebus, O. et al. Clonidine GH stimulation test to differentiate MSA from idiopathic late onset cerebellar ataxia: a prospective, controlled study. J Neurol (2020). https://doi.org/10.1007/s00415-020-09737-z

Download citation

Keywords

  • Multiple system atrophy
  • Cerebellar ataxia
  • Clonidine growth hormone test
  • Idiopathic late-onset cerebellar ataxia